BioSpace

Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reported data bolstering its case to bring to market the first CAR T for an autoimmune disease.

Por BioSpace

1 minuto de lectura
Compartir
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas